Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (August 2017)
12 slides from Corbus Pharmaceuticals's investor presentation, Aug 31, 2017
Slide 1: Developing Breakthrough Therapies for Rare Inflammatory and Fibrotic Diseases
Slide 2: Forward-Looking Statements
x Forward-Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, b
Slide 3: Anabasum: Ongoing Phase 2 Study for Treatment of Dermatomyositis
Anabasum: Ongoing Phase 2 Study for Treatm » Anabasum is in a Phase 2 study in people with skin-predominant, refractory DM - Primary outcome is change in baseline in CDASI (a standard measure of disease activity) » Data expected in Q4 2017 * Open-label extension currently underway CORBUSYY
Slide 4: Anabasum Pipeline: Multiple Opportunities in Rare Autoimmune / Inflammatory / Fibrotic Diseases
Anabasum Pipeline: Multiple Opportunities in Rare Autoimmune / Inflammatory / Fibrotic Diseases Pal Phase of | Orphan | FastTrack | Open-tabel fe | tin [oe] Stn | "East | | SpemieScersk 900 ame Retcae (ssc) (us#eu) Phase 3 y 2017 Dermatomyositis 50,000 i Phase 2 data Autoimmune (0m) (Us#EU) Phase 2
Slide 5: Rare autoimmune disorder characterized in part by abnormal innate immune responses
Rare autoimmune disorder characterized in part by abnormal innate immune responses and inflammatory changes in the skin and muscles Nay Also Aff mortality rate as high as 25%" 45 Ott, a Matem Rneunatoogy 2018:7 Reon, Sen tal BJ Demat 2016 3: Man, Chung, Fern 2012: 4% Yang 2017
Slide 6: Current Lack of Effective Therapies
x Current Lack of Effective Therapies io FDA approved lication for Current treatments m associated with significant adverse events Treatments include: antimalarials, immunosuppressive medications", intravenous immunoglobulin CORBUSYY “25. Actar Ga memaeala, myeapnente
Slide 7: Anabasum Promotes Resolution of Inflammation and Fibrotic Responses
y Anabasum Promotes Resolution of Inflammation and Fibrotic Responses Resolution of Chronic steavibise easel insets Anabasum: Triggers Resolution of Innate Immune Responses Pro.inflammatory lipids + Vasodilation edema ¥ Chemokines Pro-resolving lipid mediators Tissue infitration with ¥ Pro-resolving
Slide 8: Anabasum Reduces TNF-a and IFN-a Production by PBMC from Subjects with DM
y Anabasum Reduces TNF-a and IFN-a Production by PBMC fr /’ Subjects with DM Number of patients m8 7 mT contributing PBMC 9-17 n=16 n=16 — n=15 ‘Anabasum (uM) Anabasum (pM) ‘The median quantity of IFN-a secreted from CPG- The LPS-stimulated PBMCs of DM patients stimulated PBMCs of DM patients (8 _Ro
Slide 9: Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Cutaneous Dermatomyositis Disease Area and Severity Index /\ (CDASI) CDASI was developed to measure multiple inflammatory elements in the skin‘ Measurement Location Disease Severity scar PERIORBITAL: asta AA REST OF THE FACE {AREA NECK (FRONTAL) [ABDOMEN id 48 wes HE e== — O'cpasi scale mecnanic’s c
Slide 10: Ongoing Dermatomyositis Phase 2 Clinical Study
x Ongoing Dermatomyositis Phase 2 Clinical Study | Topline Results Expected Q4 2017 | [NIH)} National Institutes of Health Double-blind fe __ Univesity of Pennsyivania _randomized, placebo-controlled 1 Site = pccsian sensor ar mene 22 Adults 166 week study—12 week active dosing Y. F 3 s Fs x cS & [_
Slide 11: Clear Unmet Medical Need
Clear Unmet Medical Need CORBUSY
Slide 12: Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. 617.963.0100 info@co vw.corbuspharma.com 100 River Ridge Drive Norwood, MA 02062
Corbus Pharmaceuticals Holdings — Investor Presentation (August 2017) on 6ix